Jason Cole

Cole is the founding Chief Executive Officer and board member of Zag Bio, the Cambridge company that stepped out of stealth in October 2025 with $80 million and an unusually specific ambition: teach the immune system to tolerate itself by reaching the place where tolerance is born. The lead program, ZAG-101, is a bifunctional antibody that ferries a pancreatic self-antigen to the thymus to treat Type 1 diabetes. If the first one works, a discovery pipeline of other autoimmune targets follows.

What makes the appointment interesting is the resume behind it. Cole did not come up through a wet lab. He holds an A.B. in Government from Dartmouth and a J.D. from Columbia - credentials that point toward a courtroom, not a clinical pipeline. Instead he spent two decades turning legal and financial machinery into shipped medicine.

The clearest demonstration is bluebird bio. Cole arrived and held a rotating stack of C-suite titles - Chief Operating and Legal Officer, then Chief Business Officer, then Chief Strategy & Financial Officer - while the company grew from roughly 100 employees to about 1,200 across the United States and Europe. Along the way he executed equity financings with gross proceeds north of $3.7 billion and structured oncology partnerships with Celgene/Bristol Myers Squibb and Regeneron worth hundreds of millions.

The financings were a means, not the point. During those years bluebird delivered first-in-class gene and cell therapies that actually reached patients: ZYNTEGLO for beta-thalassemia, SKYSONA for cerebral adrenoleukodystrophy, ABECMA, a CAR-T therapy for relapsed and refractory multiple myeloma, and a BLA for lovo-cel in sickle cell disease. Few executives can point to a list like that, and fewer still got there without a PhD.

Before Zag Bio, Cole sat in the chief executive's chair for the first time at SalioGen Therapeutics, where he was appointed CEO and Chairman of the Board in 2023. Earlier still, he served on the executive leadership teams of Zalicus and CombinatorRx. The arc is consistent: he keeps moving toward the harder seat, and toward problems that the rest of the field has filed under "too difficult."

That instinct is what Zag Bio is really buying. The company was founded and incubated by Polaris Partners and co-led into its Series A by the T1D Fund, with a roster of strategic backers that reads like a pharma summit - AbbVie Ventures, Regeneron Ventures and Sanofi Ventures all wrote checks, alongside Mission BioCapital, Lightspeed, KdT Ventures, Boxer Capital, Pear VC and others. Money like that does not arrive for a science project. It arrives because someone is expected to turn it into a clinical program on a schedule.

Cole frames the work in patient terms rather than platform terms. "It is an exciting opportunity," he said at launch, "to join Zag Bio's outstanding team and supportive board and investors to realize the potential to transform the treatment of many autoimmune diseases by targeting the thymus." The sequence in his own words is telling: team, board, investors, patients - then the science. For a former general counsel, the people and the obligations come first.

He carries that civic streak beyond his own company. Cole serves as Vice Chair of the MassBio board, the trade organization that knits together the dense Massachusetts life-sciences cluster he keeps building inside of. It is the kind of role taken on by someone who treats the local biotech ecosystem as a shared project, not just a hiring pool.